CoDiagnostics (CODX)
(Delayed Data from NSDQ)
$1.29 USD
-0.02 (-1.53%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $1.30 +0.01 (0.78%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
Co-Diagnostics, Inc. [CODX]
Reports for Purchase
Showing records 21 - 40 ( 81 total )
Company: Co-Diagnostics, Inc.
Industry: Medical Services
1Q22 Financial Results Reported; Reiterate Buy; Modulating PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Hepatitis C Viral Load Test Receives Clearance in India; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
CODX beats 4Q21 Consensus and guidance for EPS - Reiterate Buy rating and $29 PT
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Strong Financial Performance in 4Q21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Hepatitis B Viral Load Test Approved in India; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Acquisition of All Assets of the Point-of-Care Testing Platform; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
ABC RT-PCR Test Approved in India; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
COVID-19 Assay Performance Unaffected by the New Variant; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
CODX beats 3Q21 Consensus - Advancing POC Diagnostics - Reiterate Buy rating and $29 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Co-Diagnostics, Inc.
Industry: Medical Services
New Sales Record in 3Q21; Reiterate Buy; Modulating PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Dengue-Chikungunya Multiplex Test Cleared in India; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Dengue and Chikungunya Tests Cleared in India; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Intellectual Property Portfolio Strengthened; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
COVID-19 Direct Saliva Test Obtains CE Mark; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Top- and Bottom-Line 1Q21 Beat; Volume Growth to Drive Sales; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
2020 Financial Results Reported; Reiterate Buy; Lowering PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Point-of-Care COVID-19 PCR Testing Platform in Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department